Straits Times Index
3,292.93 -3.96 (-0.12%) S&P 500
5,127.79 +63.59 (+1.26%) Dow
38,675.68 +449.98 (+1.18%) Nasdaq
16,156.33 +315.33 (+1.99%) Bitcoin USD
63,793.57 -240.15 (-0.38%) CMC Crypto 200
1,312.63 +35.65 (+2.79%)
GSK May 2024 37.000 put
| Previous close | 0.3500 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.9500 |
| Strike | 37.00 |
| Expiry date | 2024-05-31 |
| Day's range | 0.3500 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
Insider MonkeyGSK plc (NYSE:GSK) Q1 2024 Earnings Call Transcript
GSK plc (NYSE:GSK) Q1 2024 Earnings Call Transcript May 4, 2024 GSK plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Nick Stone: Hello everyone. Welcome to today’s call and webcast. The presentation was sent to our distribution list by email, and […]
Simply Wall St.GSK First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GSK ( LON:GSK ) First Quarter 2024 Results Key Financial Results Revenue: UK£7.36b (up 5.9% from 1Q 2023). Net income...
BenzingaGSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
